Personal profile
Personal profile
Dr. Noureddin completed his internal medicine residency at the University of Southern California (USC) and then moved to the National Institutes of Health (NIH), where he enrolled in a three-year hepatology fellowship at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). At NIH, he completed the NIH/Duke University Master of Health Sciences in Clinical Research program. After completing his NIH fellowship, he completed a gastroenterology fellowship at the University of California, San Diego (UCSD), where he was a T32 NIH fellow. He then joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recruited to Cedars-Sinai Medical Center in 2015 to establish its new fatty liver program. In 2022, he relocated to Texas to establish a state-of-the-art research institute.
External positions
Clinical Professor of Medicine, Weill Cornell Medicine
Nov 1 2023 → …
Divisions
- Gastroenterology and Hepatology
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Association of documented social deprivation with cardiovascular and liver outcomes in alcohol-associated liver disease
Danpanichkul, P., Pang, Y., Ibrahim, A. F., Sirimangklanurak, S., Bueso, A., Simadibrata, D. M., Chan, S. Y., Wijarnpreecha, K., Noureddin, M., Kim, D. & Liangpunsakul, S., May 2026, In: Alcohol. 132, p. 24-29 6 p.Research output: Contribution to journal › Article › peer-review
-
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M. & Abdelmalek, M. F., 2026, (Accepted/In press) In: Clinics in Liver Disease.Research output: Contribution to journal › Review article › peer-review
-
Editorial: Combination Therapies for MASH: A Step Forward or More Complexity?
Zhou, X. D., Yilmaz, Y., Noureddin, M., Luu, H. N. & Zheng, M. H., Mar 2026, In: Alimentary Pharmacology and Therapeutics. 63, 6, p. 903-904 2 p.Research output: Contribution to journal › Editorial › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
Noureddin, M., Kowdley, K. V., Odrljin, T., Bain, G., Zhao, J., Jeglinski, B., Koziel, M. J. & Loomba, R., Feb 21 2026, In: The Lancet. 407, 10530, p. 794-804 11 p.Research output: Contribution to journal › Article › peer-review
2 Link opens in a new tab Scopus citations -
Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated Steatohepatitis
Sanyal, A. J., Nakajima, A., Bugianesi, E., Sebastiani, G., Schattenberg, J. M., Adams, L. A., Noureddin, M., Yoneda, M., Bedossa, P., Younossi, Z. M., Alfadda, A. A., Geier, A., Tacke, F., Marchesini, G., Targher, G., Al-Omar, H. A., Hagström, H., Abraldes, J. G., Boursier, J. & Imajo, K. & 12 others, , 2026, (Accepted/In press) In: Clinical Gastroenterology and Hepatology.Research output: Contribution to journal › Article › peer-review
Open Access
Prizes
-
Presidential Award - Peer Reviewed Publication
Noureddin, M. (Recipient), Oct 14 2025
Prize: Prize (including medals and awards)
-
Vice Chair, AASLD - NAFLD Special Interest Group
Noureddin, M. (Recipient), Jul 1 2023
Prize: Appointment